AWP Track 2 Settlement
Pharmaceutical Industry Average Wholesale Price Litigation
Docket No. 01-CV-12257-PBS, MDL No. 1456
CLASS ACTION INFORMATIONAL WEBSITE
     

Welcome to the AWP Track 2 Settlement Website


Please Download A Copy Of The Full Notice That Applies To You. It Will Explain, In Detail, Your Rights And Options:


**Update: On December 15, 2009 the court enterd an order temporarily suspending all opt-out, objection, and claims filing deadlines for consumer class members only until further notice. Consumers can still file claims during this period and are urged to do so. If you have already filed a claim or objection, or if you have already opted-out of the class, you do not need to take any action at this time. Further updates will be posted on this website and on the toll-free settlement hotline (1-877-465-8136) as soon as the information becomes available. The suspension of deadlines has no effect on the Third Party Payor class members.**


Consumers:
If you made payments through Private Insurance,  Click Here For The Full Notice

If you made payments through Medicare Part B, Click Here For The Full Notice
Third-Party Payors:

If You Downloaded a Copy of the Notice prior to February 19, 2009. Please Download a Copy of the Amended Notice below.

Click Here For The Full Amended Notice to Third-Party Payors

There is a Proposed Class Action Settlement with various drug manufacturers (“Defendants”) concerning approximately 200 Drugs that are listed in the Covered Drugs List.This is a class action lawsuit in the U.S. District Court for the District of Massachusetts. The name of the lawsuit is In re: Pharmaceutical Average Wholesale Price Litigation, Docket No. 01-CV-12257-PBS, MDL No. 1456.

The lawsuit claims that certain drug companies reported false and inflated average wholesale prices (“AWP”) for certain types of outpatient drugs. The Average Wholesale Price (“AWP”) is used to set reimbursement amounts that are paid by a) Medicare and its beneficiaries, b) private healthy insurers, and c) consumers making full cash or percentage co-payments under private health insurance plans. The lawsuit claims that Defendants reported false and inflated AWPs for the drugs at issue, which in turn raised the price consumers, Medicare, and insurers paid for the drugs.

Defendants deny the claims in the lawsuit but have agreed to pay $125 million to settle these and other related claims. This Proposed Settlement is not an admission of wrongdoing or an indication that any law was violated. The costs of administering the Proposed Settlement as well as attorneys' fees will be deducted from the Settlement Fund before distributions to Class Members.

The remaining fund will be distributed to consumers and Third-Party Payors who submit a valid claim.


 PRIVATE INSURANCE

If You Made a full cash or a Percentage Co-Payments Through Private Health Insurance for any of These Drugs Between
1/1/91 and 3/1/08,

Click Here

         
 MEDICARE PART B

If You Made Percentage Co-Payments Through Medicare Part B for any

of These Drugs Between
1/1/91 and 1/1/05,

 

Click Here







         
 THIRD-PARTY PAYORS

If You Reimbursed for

any of These Drugs

Between
1/1/91 and 3/1/08,


Click Here